1. Home
  2. LICN vs VTGN Comparison

LICN vs VTGN Comparison

Compare LICN & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LICN

Lichen China Limited

HOLD

Current Price

$1.05

Market Cap

22.2M

Sector

N/A

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.24

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LICN
VTGN
Founded
2004
1998
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.2M
25.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
LICN
VTGN
Price
$1.05
$0.24
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$0.90
AVG Volume (30 Days)
908.8K
1.4M
Earning Date
04-28-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$0.20
52 Week High
$9.49
$5.14

Technical Indicators

Market Signals
Indicator
LICN
VTGN
Relative Strength Index (RSI) 41.61 35.18
Support Level $0.77 $0.20
Resistance Level $1.76 $0.65
Average True Range (ATR) 0.23 0.01
MACD 0.04 0.01
Stochastic Oscillator 39.52 51.75

Price Performance

Historical Comparison
LICN
VTGN

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational, and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and the sales of financial and taxation training software.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: